Lenacapavir, an antiviral drug, demonstrated 100% efficacy in preventing new HIV infections in women with just two annual subcutaneous injections. The results were presented at the IAS Conference and published in The New England Journal of Medicine.
The drug, similar to a vaccine, received a standing ovation at the conference, signaling a historic moment in the battle against HIV. Gilead's opportunity to make a significant impact on ending AIDS is highly anticipated.
Collection
[
|
...
]